United States securities and exchange commission logo




                                                                                
                           March 4, 2024

       Sujal Patel
       Chief Executive Officer
       Nautilus Biotechnology, Inc.
       2701 Eastlake Avenue East
       Seattle, Washington 98102

                                                        Re: Nautilus 
Biotechnology, Inc.
                                                            Registration 
Statement on Form S-3
                                                            Filed February 28, 
2024
                                                            File No. 333-277437

       Dear Sujal Patel:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Jessica 
Ansart at 202-551-4511 with any questions.



                                                                                
                           Sincerely,

                                                                                
                           Division of Corporation Finance
                                                                                
                           Office of Industrial Applications and
                                                                                
                           Services
       cc:                                              Zachary Myers